# Engineered bacteria that live in tumours and manufacture drugs there

Source: https://onco.cc/ideas/idea-bio2-engineered-bacteria-payloads/  
OnCo record `idea-bio2-engineered-bacteria-payloads` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Some harmless bacteria naturally grow in the low-oxygen core of tumours. Engineering them to produce immune-activating drugs turns them into tiny factories inside the tumour.

## Summary

Attenuated Salmonella and E. coli Nissle strains colonise hypoxic tumour cores selectively, and synthetic biology allows quorum-controlled payload release of STING agonists, CD47 nanobodies or cytokines. Early human experience with intratumoural bacterial therapy exists, and BCG in bladder cancer is a century-old proof that live bacteria can drive anti-tumour immunity. Safety, biocontainment and manufacturing are the real hurdles.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A quorum-regulated engineered strain colonises human tumours at detectable levels after intravenous or intratumoural dosing and produces measurable local payload and immune activation without bacteraemia above grade 2.
- Rationale: Tumour hypoxia is a selectivity handle that no small molecule can match, and payload release can be genetically gated to bacterial density inside the lesion. Escalating dose is a colonisation problem rather than a plasma exposure problem.
- Proposed test: First-in-human intratumoural dosing in accessible lesions with quantitative colonisation, payload and safety endpoints, plus a documented kill-switch demonstration.
- Maturity: preclinical-evidence
- Actor: industry

## Sources

- Bottleneck evidence (Cold tumours and the immunosuppressive microenvironment): Haslam & Prasad, Estimation of the percentage of US patients eligible for and responding to checkpoint inhibitors (JAMA Netw Open 2019): https://doi.org/10.1001/jamanetworkopen.2019.2535

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Cytokines & engineered cytokines](https://onco.cc/technologies/cytokine-therapy/), [Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy)](https://onco.cc/technologies/bcg-and-intravesical-therapy/), [STING & innate immune agonists](https://onco.cc/technologies/sting-agonist/)
- targets: [CD47](https://onco.cc/targets/cd47/)
- drugs: [Intravesical BCG](https://onco.cc/drugs/bcg-intravesical/)
- bottlenecks: [Cold tumours and the immunosuppressive microenvironment](https://onco.cc/bottlenecks/b-tme-immunosuppression/), [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/)
- key papers: [Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs](https://onco.cc/key-papers/paper-haslam-jama-netw-open/), [Expression and Clinical Significance of CD47 in Colorectal Cancer: A Review](https://onco.cc/key-papers/paper-cd47-colorectal-cancers-basel-2025/), [Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade](https://onco.cc/key-papers/paper-cd47-pancreatic-pharmacol-res-2022/), [Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer](https://onco.cc/key-papers/paper-cd47-colorectal-cancer-res-commun-2025/)

---
JSON: https://onco.cc/api/v1/entities/idea-bio2-engineered-bacteria-payloads.json